Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOLLARS study: HIV-1 RNA decay in semen and rectum with DTG/3TC vs BIC/FTC/TAF
2019-004109-28Phase 4Active
- Sponsor
- Daniel Podzamczer Palter
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in human immunodeficiency virus infection (HIV) comparing Dolutegravir + lamivudine with Bictegravir/emtricitabine/tenofovir alafenamide (2 arms). Primary endpoint: HIV-1 RNA decay in seminal plasma. Started Dec 2019; status: active.
02
Drugs
dolutegravirlamivudinebictegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-004109-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004109-28.